Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Gross Profit (2017 - 2024)

Avalo Therapeutics (AVTX) has disclosed Gross Profit for 8 consecutive years, with -$465000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Gross Profit fell 4550.0% year-over-year to -$465000.0, compared with a TTM value of -$96000.0 through Sep 2024, down 176.8%, and an annual FY2023 reading of $640000.0, down 95.62% over the prior year.
  • Gross Profit was -$465000.0 for Q3 2024 at Avalo Therapeutics, down from -$343000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $14.4 million in Q3 2022 and bottomed at -$623423.0 in Q4 2020.
  • Average Gross Profit over 5 years is $1.1 million, with a median of $38000.0 recorded in 2021.
  • The sharpest move saw Gross Profit soared 3162.67% in 2022, then tumbled 4550.0% in 2024.
  • Year by year, Gross Profit stood at -$623423.0 in 2020, then soared by 67.12% to -$205000.0 in 2021, then soared by 235.12% to $277000.0 in 2022, then soared by 185.92% to $792000.0 in 2023, then plummeted by 158.71% to -$465000.0 in 2024.
  • Business Quant data shows Gross Profit for AVTX at -$465000.0 in Q3 2024, -$343000.0 in Q2 2024, and -$80000.0 in Q1 2024.